RetroSearch Browse

Home - News ( United States | United Kingdom | Italy | Germany ) - Football scores

Showing content from https://patents.google.com/patent/SG11201501774QA/en below:

SG11201501774QA - Methods of treating alzheimer's disease and pharmaceutical compositions thereof

SG11201501774QA - Methods of treating alzheimer's disease and pharmaceutical compositions thereof - Google PatentsMethods of treating alzheimer's disease and pharmaceutical compositions thereof Info

Publication number: SG11201501774QA
Authority: SG; Singapore
Prior art keywords: disease; methods; pharmaceutical compositions; treating alzheimer; alzheimer
Prior art date: 2012-09-09

Application number

SG11201501774QA

Inventor

Ellen Schmidt

Johan Areberg

Original Assignee

Lundbeck & Co As H

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2012-09-09

Filing date

2013-09-06

Publication date

2015-05-28

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=49118521&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SG11201501774Q(A) "Global patent litigation datasetâ by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2013-09-06 Application filed by Lundbeck & Co As H filed Critical Lundbeck & Co As H

2015-05-28 Publication of SG11201501774QA publication Critical patent/SG11201501774QA/en

Links

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
- A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/27—Esters, e.g. nitroglycerine, selenocyanates of carbamic or thiocarbamic acids, meprobamate, carbachol, neostigmine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00Â -Â A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Chemical & Material Sciences (AREA)
Epidemiology (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Biomedical Technology (AREA)
Neurosurgery (AREA)
Neurology (AREA)
Chemical Kinetics & Catalysis (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Emergency Medicine (AREA)
Hospice & Palliative Care (AREA)
Psychiatry (AREA)
Nutrition Science (AREA)
Physiology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

SG11201501774QA 2012-09-09 2013-09-06 Methods of treating alzheimer's disease and pharmaceutical compositions thereof SG11201501774QA (en) Applications Claiming Priority (3) Application Number Priority Date Filing Date Title US201261698664P 2012-09-09 2012-09-09 US201361782084P 2013-03-14 2013-03-14 PCT/EP2013/068516 WO2014037532A1 (en) 2012-09-09 2013-09-06 Methods of treating alzheimer's disease and pharmaceutical compositions thereof Publications (1) Family ID=49118521 Family Applications (1) Application Number Title Priority Date Filing Date SG11201501774QA SG11201501774QA (en) 2012-09-09 2013-09-06 Methods of treating alzheimer's disease and pharmaceutical compositions thereof Country Status (34) Families Citing this family (29) * Cited by examiner, â Cited by third party Publication number Priority date Publication date Assignee Title EP1558582B1 (en) 2003-07-22 2005-12-21 Arena Pharmaceuticals, Inc. Diaryl and arylheteroaryl urea derivatives as modulators of the 5-ht2a serotonin receptor useful for the prophylaxis and treatment of disorders related thereto EP2508177A1 (en) 2007-12-12 2012-10-10 Glaxo Group Limited Combinations comprising 3-phenylsulfonyl-8-piperazinyl-1yl-quinoline US20110021538A1 (en) 2008-04-02 2011-01-27 Arena Pharmaceuticals, Inc. Processes for the preparation of pyrazole derivatives useful as modulators of the 5-ht2a serotonin receptor US9126946B2 (en) 2008-10-28 2015-09-08 Arena Pharmaceuticals, Inc. Processes useful for the preparation of 1-[3-(4-bromo-2-methyl-2H-pyrazol-3-yl)-4-methoxy-phenyl]-3-(2,4-difluoro-phenyl)urea and crystalline forms related thereto JO3459B1 (en) 2012-09-09 2020-07-05 H Lundbeck As Pharmaceutical formulations for the treatment of Alzheimer's disease BR112015019720B8 (en) 2013-03-14 2023-10-10 Boehringer Ingelheim Int Substituted 2-azabicyclo[2.2.1]heptane-3-carboxylic acid (benzyl-cyano-methyl)-amide inhibitors of cathepsin and pharmaceutical composition TWI644671B (en) 2013-03-14 2018-12-21 æ¯å©æåå¥çè¥åå¬å¸ P2X7 regulator EP3321266A1 (en) 2013-03-14 2018-05-16 Janssen Pharmaceutica NV P2x7 modulators JO3509B1 (en) 2013-03-14 2020-07-05 Janssen Pharmaceutica Nv P2x7 modulators WO2014152537A1 (en) 2013-03-14 2014-09-25 Janssen Pharmaceutica Nv P2x7 modulators JO3639B1 (en) * 2014-07-04 2020-08-27 H Lundbeck As Novel polymorphic form of N-[2-(6-fluoro-lH-indol-3-yl)ethyl]-3-(2,2,3,3-tetrafluoropropoxy)benzylamine hydrochloride CN108047240B (en) 2014-09-12 2020-08-04 åææ ¼æ®·æ ¼ç¿°å½éæéå¬å¸ Spirocyclic compound inhibitors of cathepsin C JP6592510B2 (en) 2014-09-12 2019-10-16 ã¤ã³ã»ã³ ãã¡ã¼ãã·ã¥ã¼ãã£ã« ã¨ãï¼ãã¼ï¼ P2X7 regulator CN105175307A (en) * 2014-11-18 2015-12-23 èå·æ¶äºè¯ç©ç§ææéå¬å¸ Lu AE58054 hydrochloride crystal form A, preparation method and uses thereof MX2017014191A (en) * 2015-05-07 2018-08-01 Axovant Sciences Gmbh Methods of treating a neurodegenerative disease. RU2017145976A (en) 2015-06-12 2019-07-15 ÐÐºÑÐ¾Ð²Ð°Ð½Ñ Ð¡Ð°Ð¹ÐµÐ½ÑÐ¸Ð· ÐÐ¼Ð±Ñ Diaryl- and arylheteroarylurea derivatives applicable for the prevention and treatment of behavioral disturbances during the REM phase of sleep BR112018000728A2 (en) 2015-07-15 2018-09-04 Axovant Sciences Gmbh method for the prophylaxis and / or treatment of visual hallucinations in a subject in need CN109069650A (en) * 2016-04-26 2018-12-21 H.éå¾·è´åæéå¬å¸ Acetylcholinesterase inhibitor and Ida Shandong pyridine are used to reduce the purposes of parkinsonian's tumble US10864191B2 (en) * 2016-05-11 2020-12-15 H. Lundbeck A/S 5-HT6 receptor antagonists for use in the treatment of Alzheimer's disease with apathy as comorbidity US11458135B2 (en) 2016-05-18 2022-10-04 Suven Life Sciences Limited Combination of pure 5-HT6 receptor antagonists with acetylcholinesterase inhibitors CN106309436A (en) * 2016-07-25 2017-01-11 å®æ³¢å¤§å¦ Tryptamine derivative capable of serving as acetylcholin esterase inhibitor and application of derivative CN107118146B (en) * 2017-04-13 2019-09-03 å®æ³¢å¤§å¦ A kind of 6-bromotryptamine derivative and its preparation method and application DK3630098T3 (en) * 2017-05-24 2021-04-26 H Lundbeck As COMBINATION OF A 5-HT6 RECEPTOR ANTAGONIST AND AN ACETYLCHOLINE INSTERATION INHIBITOR FOR USE IN THE TREATMENT OF ALZHEIMER'S DISEASE IN A PATIENT SUBPOPULATION HAVING APOE4 ALLOYS EP3856178A1 (en) 2018-09-28 2021-08-04 Janssen Pharmaceutica NV Monoacylglycerol lipase modulators BR112021005936A2 (en) 2018-09-28 2021-06-29 Janssen Pharmaceutica Nv monoacylglycerol lipase modulators KR20220075386A (en) 2019-09-30 2022-06-08 ìì¼ íë§ìí°ì¹´ ì.ë¸ì´. Radiolabeled MGL PET Ligand NL2024431B1 (en) 2019-12-11 2021-09-07 Sulfateq Bv Compounds for treatment of alzheimerâs disease CA3176946A1 (en) 2020-03-26 2021-09-30 Janssen Pharmaceutica Nv Monoacylglycerol lipase modulators EP3960174B1 (en) 2020-08-28 2024-10-30 WestfÃ¤lische Wilhelms-UniversitÃ¤t MÃ¼nster Parasympathetic active phenyl-glycosid-substituted hydroxy-methyl-piperidine and -pyrrolidine alkaloids for medicinal use Family Cites Families (21) * Cited by examiner, â Cited by third party Publication number Priority date Publication date Assignee Title US3597149A (en) 1969-04-29 1971-08-03 Showa Denko Kk Inhibition of gas-fume fading of dyed cellulose acetate material FR2181559A1 (en) 1972-04-28 1973-12-07 Aec Chimie Organique Bio N-Phenylalkyl-N-3-indolylalkyl-alkylamines - with sedative, neuroleptic, analgesic, hypotensive, antiserotonin, adrenolytic activity JPS5764632A (en) 1980-10-09 1982-04-19 Mitsui Toatsu Chem Inc Novel 2-arylethyl ether derivative and thioether derivative, their production and insecticide and acaricide DE3632329A1 (en) 1986-09-24 1988-03-31 Bayer Ag SUBSTITUTED PHENYLSULPHONAMID US5202336A (en) 1986-09-24 1993-04-13 Bayer Aktiengesellschaft Antiflammatory quinolin methoxy phenylsulphonamides SE9103745D0 (en) 1991-12-18 1991-12-18 Wikstroem Haakan ARYL-TRIFLATES AND RELATED COMPOUNDS DE69411143T2 (en) 1993-09-01 1998-10-22 Allelix Biopharma TRYPTAMINE ANALOGS WITH 5-HT1D SELECTIVITY US5504101A (en) 1994-05-06 1996-04-02 Allelix Biopharmaceuticals, Inc. 5-HT-1D receptor ligands CA2302412C (en) 1997-09-29 2005-12-20 Aventis Pharmaceuticals Inc. Aminoalkylphenol derivatives and related compounds GB9820113D0 (en) 1998-09-15 1998-11-11 Merck Sharp & Dohme Therapeutic agents EP1149078B1 (en) 1998-12-11 2006-03-08 Virginia Commonwealth University Selective 5-ht 6 receptor ligands PL349348A1 (en) 1999-01-13 2002-07-15 Millennium Pharmaceuticals Functionalized heterocycles as chemokine receptor modulators US6750348B1 (en) 1999-03-24 2004-06-15 Anormed, Inc. Chemokine receptor binding heterocyclic compounds CA2442114C (en) 2001-03-29 2011-06-21 Eli Lilly And Company N-(2-arylethyl)benzylamines as antagonists of the 5-ht6 receptor RU2252936C2 (en) * 2002-12-05 2005-05-27 ÐÐ½ÑÑÐ¸ÑÑÑ ÑÐ¸Ð·Ð¸Ð¾Ð»Ð¾Ð³Ð¸ÑÐµÑÐºÐ¸ Ð°ÐºÑÐ¸Ð²Ð½ÑÑ Ð²ÐµÑÐµÑÑÐ² Ð ÐÐ S-substituted [(hetero)aryl]alkylisothioureas, production thereof, pharmaceutical composition, investigation of glutamatergic system, treatment methods (variants) PE20071143A1 (en) 2006-01-13 2008-01-20 Wyeth Corp PHARMACEUTICAL COMPOSITION INCLUDING AN ACETYLCHOLINESTERASE INHIBITOR AND A 5-HYDROXITRIPTAMINE-6 ANTAGONIST CN101500611A (en) 2006-06-23 2009-08-05 åæ¯èç»´å®éªå®¤è¡ä»½æéå¬å¸ Combination of a cholinesterase inhibitor and a compound with 5-HT6 receptor affinity AR061637A1 (en) 2006-06-26 2008-09-10 Epix Delaware Inc SNC DISORDER TREATMENT COMPOSITIONS AND METHODS AU2010275431A1 (en) * 2009-07-23 2012-02-23 Shire Llc Galantamine amino acid and peptide prodrugs and uses thereof TW201139370A (en) 2009-12-23 2011-11-16 Lundbeck & Co As H Processes for the manufacture of a pharmaceutically active agent JO3459B1 (en) 2012-09-09 2020-07-05 H Lundbeck As Pharmaceutical formulations for the treatment of Alzheimer's disease

2013
- 2013-08-21 JO JOP/2013/0248A patent/JO3459B1/en active
- 2013-09-06 SG SG11201501774QA patent/SG11201501774QA/en unknown
- 2013-09-06 PL PL13759195T patent/PL2892563T3/en unknown
- 2013-09-06 WO PCT/EP2013/068516 patent/WO2014037532A1/en active Application Filing
- 2013-09-06 AP AP2015008306A patent/AP2015008306A0/en unknown
- 2013-09-06 AU AU2013311573A patent/AU2013311573B2/en active Active
- 2013-09-06 DK DK13759195.4T patent/DK2892563T3/en active
- 2013-09-06 SM SM20180678T patent/SMT201800678T1/en unknown
- 2013-09-06 BR BR112015005117-0A patent/BR112015005117B1/en active IP Right Grant
- 2013-09-06 LT LTEP13759195.4T patent/LT2892563T/en unknown
- 2013-09-06 GE GEAP201313752A patent/GEP201706776B/en unknown
- 2013-09-06 MY MYPI2015000575A patent/MY182539A/en unknown
- 2013-09-06 JP JP2015530420A patent/JP6693744B2/en active Active
- 2013-09-06 CN CN201380046768.6A patent/CN104619344A/en active Pending
- 2013-09-06 SI SI201331303T patent/SI2892563T1/en unknown
- 2013-09-06 NZ NZ630589A patent/NZ630589A/en unknown
- 2013-09-06 RU RU2015107877A patent/RU2675786C2/en active
- 2013-09-06 KR KR1020157007345A patent/KR20150065680A/en not_active Ceased
- 2013-09-06 RS RS20181571A patent/RS58104B1/en unknown
- 2013-09-06 CA CA2883751A patent/CA2883751C/en active Active
- 2013-09-06 PT PT13759195T patent/PT2892563T/en unknown
- 2013-09-06 EA EA201590353A patent/EA030448B1/en not_active IP Right Cessation
- 2013-09-06 TW TW102132182A patent/TWI632909B/en active
- 2013-09-06 EP EP13759195.4A patent/EP2892563B1/en active Active
- 2013-09-06 KR KR1020207034028A patent/KR102342127B1/en active Active
- 2013-09-06 MX MX2015002879A patent/MX368305B/en active IP Right Grant
- 2013-09-06 ES ES13759195T patent/ES2703630T3/en active Active
- 2013-09-09 US US14/021,033 patent/US9375418B2/en active Active
2015
- 2015-02-23 IL IL237369A patent/IL237369B/en active IP Right Grant
- 2015-03-02 TN TNP2015000076A patent/TN2015000076A1/en unknown
- 2015-03-06 NI NI201500031A patent/NI201500031A/en unknown
- 2015-03-06 CL CL2015000578A patent/CL2015000578A1/en unknown
2016
- 2016-01-07 HK HK16100112.5A patent/HK1212217A1/en unknown
- 2016-03-30 US US15/084,712 patent/US9687473B2/en active Active
- 2016-06-28 US US15/194,947 patent/US9789085B2/en active Active
2017
- 2017-09-06 US US15/696,880 patent/US10660878B2/en active Active
2018
- 2018-12-06 HR HRP20182069TT patent/HRP20182069T1/en unknown
- 2018-12-06 JP JP2018228631A patent/JP2019059760A/en active Pending
- 2018-12-21 CY CY181101390T patent/CY1121062T1/en unknown

Also Published As Similar Documents Publication Publication Date Title IL237369A0 (en) 2015-04-30 Methods of treating alzheimer's disease and pharmaceutical compositions thereof IL266582A (en) 2019-07-31 Compositions and methods for the treatment of hemoglobinopathies EP2707369A4 (en) 2014-12-10 Compositions and methods for treating alzheimer's disease IL236221A (en) 2017-12-31 Thienopyridone derivatives and pharmaceutical compositions comprising them for the treatment of diseases HK1213494A1 (en) 2016-07-08 Combination therapy for treating Alzheimer's disease and related diseases HK1214832A1 (en) 2016-08-05 Compositions and methods for treatment of metabolic disorders and diseases HUE041553T2 (en) 2019-05-28 Methods and compositions for the treatment of monogenic diseases IL236054B (en) 2021-03-25 Compositions and methods for treating crohn's disease and related conditions and infections HK1246660A1 (en) 2018-09-14 Methods and drug products for treating alzheimer's disease EP2819687A4 (en) 2015-09-30 Compositions and methods for treatment of peripheral vascular disease ZA201406209B (en) 2016-01-27 Methods and compositions for treating huntington's disease ZA201406145B (en) 2016-06-29 Morpholinoalkyl fumarate compounds, pharmaceutical compositions, and methods of use SG11201403272YA (en) 2014-08-28 Compositions and methods for treating alzheimer's disease EP3628326C0 (en) 2024-02-28 Methods and materials for treatment of pompe's disease HK1198909A1 (en) 2015-06-19 Compositions and methods for the treatment of hepatic diseases and disorders HK1206623A1 (en) 2016-01-15 Pharmaceutical compositions and treatment of mastitis IL234606B (en) 2021-04-29 Novel methods and composition for treatment of disease GB201310150D0 (en) 2013-07-24 Methods and compositions relating to alzheimer's disease EP2568811A4 (en) 2014-03-12 Treatment of mci and alzheimer's disease SG10201704712QA (en) 2017-07-28 Novel pharmaceutical formulations and their use in the treatment of periodontal disease IL237730B (en) 2018-10-31 Treatment of mild and moderate alzheimer's disease PL2892556T3 (en) 2019-11-29 Compositions and methods relating to the treatment of diseases EP2709632A4 (en) 2015-03-04 Compositions and methods for the treatment of skin diseases GB201101088D0 (en) 2011-03-09 L-carnosine and cinnamon extract for the treatment of Alzheimer's Disease GB201113718D0 (en) 2011-09-21 Treatment of Dupuytren's Disease

RetroSearch is an open source project built by @garambo | Open a GitHub Issue

Search and Browse the WWW like it's 1997 | Search results from DuckDuckGo

HTML: 3.2 | Encoding: UTF-8 | Version: 0.7.4